Drug intelligence / Profile preview

esketamine + sulfentanil + remifentanil

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous (primary), Intranasal (for Esketamine Individually)
01

Overview

Esketamine + sulfentanil + remifentanil is a combination of three pharmaceutical agents used primarily in anesthesia and analgesia. Esketamine is an NMDA receptor antagonist with both analgesic and antidepressant properties, often used for its rapid-acting effects on pain and mood. Sufentanil and remifentanil are potent synthetic opioid agonists at the mu-opioid receptor, providing strong analgesia during surgical procedures or intensive care. This combination may be considered for multimodal anesthesia or advanced pain management strategies, leveraging the synergistic effects of NMDA antagonism (esketamine) to reduce opioid requirements (sufentanil, remifentanil), improve hemodynamic stability, minimize tolerance development, and enhance postoperative recovery.

02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on esketamine + sulfentanil + remifentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on esketamine + sulfentanil + remifentanil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call